The evolving model of care for familial hypercholesterolaemia

Abstract

Get full access to this article

View all access options for this article.

References

Wierzbicki

Watts

. The hinterland of familial hypercholesterolaemia: what do we not know? Curr Opin Lipidol 2015; 26: 475–483.

Pećin

Hartgers

Hovingh

Dent

Reiner

. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prevent Cardiol 2017. 24: 1383–1401.

Bell

Watts

. Progress in the care of familial hypercholesterolaemia: 2016. Med J Aust 2016; 205: 232–236.

Gidding

Champagne

de Ferranti

et al.

The agenda for familial hypercholesterolemia - a scientific statement from the American Heart Association. Circulation 2015; 136(1): 132–132.

Watts

Gidding

Wierzbicki

et al.

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171: 309–325.

de Ferranti

Rodday

Mendelson

Wong

Leslie

Sheldrick

. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016; 133: 1067–1072.

Watts

Shaw

Pang

Magliano

Jennings

GLR

Carrington

. Prevalence and treatment of familial hypercholesterolemia in Australian communities. Int J Cardiol 2015; 185: 69–71.

Benn

Watts

Tybjærg-Hansen

Nordestgaard

. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37(17): 1384–1394.

Nordestgaard

Benn

. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J 2017; 38: 1580–1583.

10.

Martin

Bell

Brett

Watts

. Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. Curr Opin Lipidol. Epub ahead of print 19 April 2017. DOI: 10.1097/MOL.0000000000000423.

11.

Pang

Poulter

Bell

et al.

Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol 2015; 9: 703–708.

12.

Nanchen

Gencer

Auer

et al.

Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J 2015; 36: 2438–2445.

13.

Kerr

Pears

Miedzybrodzka

et al.

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. Epub ahead of print 6 April 2017. DOI: 10.1093/eurheartj/ehx111.

14.

Lázaro

Pérez de Isla

Watts

et al.

Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol 2017; 11: 260–271.

15.

Morris

Wald

. The evaluation of cascade testing for familial hypercholesterolemia. Amer J Med Gen A 2012; 158: 78–84.

16.

Klančar

Grošelj

Kovač

et al.

Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol 2015; 66: 1250–1257.

17.

Wald

Bestwick

Morris

Whyte

Jenkins

Wald

. Child–Parent familial hypercholesterolemia screening in primary care. N Engl J Med 2016; 375: 1628–1637.

18.

Ahmad

Andersen

et al.

US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol 2016; 10: 1223–1229.

19.

Nordestgaard

Chapman

. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013; 34(45): 3478–90a.

20.

Sjouke

Kusters

Kindt

et al.

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome. Eur Heart J 2015; 36(9): 560–565.

21.

Santos

Gidding

Hegele

et al.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4: 850–861.

22.

Sharifi

Futema

Nair

Humphries

. Genetic architecture of familial hypercholesterolaemia. Curr Cardiol Rep 2017; 19: 44–44.

23.

Khera

Won

H-H

Peloso

et al.

Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67: 2578–2589.

24.

Abul-Husn

Manickam

Jones

et al.

Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 2016; 354(6319): aaf7000–aaf7000.

25.

Sharifi

Higginson

Bos

et al.

Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. Atherosclerosis. Epub ahead of print 13 May 2017. DOI: 10.1016/j.atherosclerosis.2017.05.015.

26.

Talmud

Shah

Whittall

et al.

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381: 1293–1301.

27.

Schwartz

Williams

Murray

. Adding protective genetic variants to clinical reporting of genomic screening results: restoring balance. JAMA 2017; 317: 1527–1528.

28.

Burns

Yeates

Spinks

Semsarian

Ingles

. Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. Eur J Hum Genet 2017; 25: 809–815.

29.

Alonso

Andres

Mata

et al.

Lipoprotein (a) levels in familial hypercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation. J Am Coll Cardiol 2014; 63: 1982–1989.

30.

Pérez de Isla

Alonso

Mata

et al.

Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART Registry. Circulation 2017; 135: 2133–2144.

31.

Sijbrands

Nieman

Budoff

. Cardiac computed tomography imaging in familial hypercholesterolemia: implications for therapy and clinical trials. Curr Opin Lipidol 2015; 26: 586–592.

32.

Williams

Hunter

Shah

et al.

Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol 2016; 67: 1759–1768.

33.

Cannon

Blazing

Giugliano

et al.

Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

34.

Sabatine

Giugliano

Keech

et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

35.

Orringer

Jacobson

Saseen

et al.

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. Epub ahead of print 19 May 2017. DOI: 10.1016/j.jacl.2017.05.001.

36.

Jellinger

Handelsman

Rosenblit

et al.

American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract 2017; 23: 1–87.

37.

Nicholls

Puri

Anderson

et al.

Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373–2384.

38.

Villa

Lothgren

Kutikova

et al.

Cost-Effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther 2017; 39: 771–786.e3.

39.

National Institute for Health and Clinical Excellence (NICE). Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia, 2016. Available at: https://www.nice.org.uk/guidance/ta394 (accessed 26 June 2017).

40.

National Institute for Health and Clinical Excellence (NICE). Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia, 2016. Available at: https://www.nice.org.uk/guidance/ta393 (accessed 26 June 2017).

41.

Baum

Toth

Underberg

Jellinger

Ross

Wilemon

. PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers. Clin Cardiol 2017; 40(4): 243–254.

42.

de Ferranti

Rodday

Parsons

et al.

Cholesterol screening and treatment practices and preferences: a survey of United States pediatricians. J Pediatr 2017; 185: 99–105.e2.

43.

Avis

Hutten

Twickler

et al.

Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn?

Curr Opin Lipidol 2009; 20: 484–490.

44.

Karalis

Hill

Clifton

Wild

. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol 2016; 10: 1081–1090.

45.

The US FH Foundation, 2017. Available at: https://thefhfoundation.org/ (accessed 26 June 2017).

46.

The European FH Patient Network, 2016. Available at: https://heartuk.org.uk/policy-and-public-affairs/european-fh-patient-network (accessed 26 June 2017).

47.

Bellgard

Walker

Napier

et al.

Design of the Familial Hypercholesterolaemia Australasia Network Registry: creating opportunities for greater international collaboration. J Atheroscler Thromb. Epub ahead of print 24 March 2017. DOI: 10.5551/jat.37507.

48.

Vallejo-Vaz

Akram

Kondapally Seshasai

et al.

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl 2016; 22: 1–32.

49.

Ellis

Pang

Watts

. Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia. Eur J Prevent Cardiol 2016; 24: 133–136.

50.

deGoma

Ahmad

O'Brien

et al.

Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. Circ Cardiovasc Genet 2016; 9: 240–249.

51.

Ramaswami

Cooper

Humphries

. The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data. Arch Dis Child 2016; 102: 255–260.

52.

Ellis

Hooper

Burnett

Watts

. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nat Rev Endocrinol 2016; 12: 467–484.